Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | B2M |
| Variant | S14fs |
| Impact List | frameshift |
| Protein Effect | loss of function |
| Gene Variant Descriptions | B2M S14fs results in a change in the amino acid sequence of the B2m protein beginning at aa 14 of 119, likely resulting in premature truncation of the functional protein (UniProt.org). S14fs confers a loss of function to the B2m protein as demonstrated by lack of MHC class I membrane localization (PMID: 27433843, PMID: 29070816). |
| Associated Drug Resistance | Y |
| Category Variants Paths |
B2M mutant B2M inact mut B2M S14fs |
| Transcript | NM_004048.4 |
| gDNA | chr15:g.(44711585_44711586) |
| cDNA | c.(40_39) |
| Protein | p.S14fs |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| XM_005254549.3 | chr15:g.(44711585_44711586) | c.(40_39) | p.S14fs | RefSeq | GRCh38/hg38 |
| XM_005254549 | chr15:g.(44711585_44711586) | c.(40_39) | p.S14fs | RefSeq | GRCh38/hg38 |
| NM_004048.2 | chr15:g.(44711585_44711586) | c.(40_39) | p.S14fs | RefSeq | GRCh38/hg38 |
| NM_004048 | chr15:g.(44711585_44711586) | c.(40_39) | p.S14fs | RefSeq | GRCh38/hg38 |
| XM_005254549.4 | chr15:g.(44711585_44711586) | c.(40_39) | p.S14fs | RefSeq | GRCh38/hg38 |
| NM_004048.4 | chr15:g.(44711585_44711586) | c.(40_39) | p.S14fs | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| B2M mutant | colorectal cancer | predicted - sensitive | unspecified PD-1 antibody | Clinical Study - Cohort | Actionable | In a clinical study, a cohort of colorectal cancer patients harboring B2M mutations demonstrated a clinical benefit of either a partial response or stable disease in 85% (11/13) when treated with a PD-1 or PD-L1 inhibitor (PMID: 31008436). | 31008436 |
| B2M mutant | colorectal cancer | predicted - sensitive | unspecified PD-L1 antibody | Clinical Study - Cohort | Actionable | In a clinical study, a cohort of colorectal cancer patients harboring B2M mutations demonstrated a clinical benefit of either a partial response or stable disease in 85% (11/13) when treated with a PD-1 or PD-L1 inhibitor (PMID: 31008436). | 31008436 |